Reduction of cutaneous photosensitivity by application of ointment containing ferrous or cobaltous ions concomitant with the use of topical protoporphyrin IX precursors

Photodiagnosis and Photodynamic Therapy

Volumn 7, Issue 3, 2010, Pages 152-157

  Juzenas, Petras ^a   Juzeniene, Asta ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

5 Aminolevulinic acid; Ferrochelatase; Fluorescence; Photodynamic therapy; Protoporphyrin IX

Indexed keywords

AMINOLEVULINIC ACID; COBALT SULFATE; FERROUS SULFATE; PROTOPORPHYRIN; ZINC SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG CLEARANCE; DRUG TISSUE LEVEL; FEMALE; FLUORESCENCE SPECTROSCOPY; MOUSE; NONHUMAN; PHOTODERMATOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SKIN PHOTOSENSITIVITY;

ADMINISTRATION, CUTANEOUS; AMINOLEVULINIC ACID; ANIMALS; COBALT; FEMALE; FERROUS COMPOUNDS; MICE; MICE, INBRED BALB C; PHOTOSENSITIVITY DISORDERS; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; SPECTROMETRY, FLUORESCENCE; ZINC SULFATE;

MUS;

EID: 77956009587     PISSN: 15721000     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2010.06.003     Document Type: Article

References (47)

1. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B 1997, 39(1):1-18.
2. Spikes J.D. Photodynamic action: from Paramecium to photochemotherapy. Photochem Photobiol 1997, 65S:142S-147S.
3. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J Natl Cancer Inst 1998, 90(12):889-905.
4. Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat Rev Cancer 2003, 3(5):380-387.
5. Palumbo G. Photodynamic therapy and cancer: a brief sightseeing tour. Expert Opin Drug Deliv 2007, 4(2):131-148.
6. Braathen L.R., Szeimies R.M., Basset-Seguin N., et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007, 56(1):125-143.
7. Thunell S. Porphyrins, porphyrin metabolism and porphyrias. I. Update. Scand J Clin Lab Invest 2000, 60(7):509-540.
8. Kennedy J.C., Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992, 14(4):275-292.
9. Kennedy J.C., Marcus S.L., Pottier R.H. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg 1996, 14(5):289-304.
10. Peng Q., Warloe T., Berg K., et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997, 79(12):2282-2308.
11. Lang K., Schulte K.W., Ruzicka T., Fritsch C. Aminolevulinic acid (Levulan) in photodynamic therapy of actinic keratoses. Skin Therapy Lett 2001, 6(10):1-2. 5.
12. Gardlo K., Ruzicka T. Metvix (PhotoCure). Curr Opin Invest Drugs 2002, 3(11):1672-1678.
13. Szeimies R.M. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol Clin 2007, 25(1):89-94.
14. Klein A., Babilas P., Karrer S., Landthaler M., Szeimies R.M. Photodynamic therapy in dermatology-an update 2008. J Dtsch Dermatol Ges 2008, 6(10):839-846.
15. Stapleton M., Rhodes L.E. Photosensitizers for photodynamic therapy of cutaneous disease. J Dermatolog Treat 2003, 14(2):107-112.
16. Angell-Petersen E., Christensen C., Muller C.R., Warloe T. Phototoxic reaction and porphyrin fluorescence in skin after topical application of methyl aminolaevulinate. Br J Dermatol 2007, 156(2):301-307.
17. Orenstein A., Kostenich G., Malik Z. The kinetics of protoporphyrin fluorescence during ALA-PDT in human malignant skin tumors. Cancer Lett 1997, 120(2):229-234.
18. van der Veen N., De Bruijn H.S., Star W.M. Photobleaching during and re-appearance after photodynamic therapy of topical ALA-induced fluorescence in UVB-treated mouse skin. Int J Cancer 1997, 72(1):110-118.
19. Star W.M., van't Veen A.J., Robinson D.J., Munte K., de Haas E.R., Sterenborg H.J. Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up. Acta Derm Venereol 2006, 86(5):412-417.
20. Golub A.L., Gudgin Dickson E.F., Kennedy J.C., Marcus S.L., Park Y., Pottier R.H. The monitoring of ALA-induced protoporphyrin IX accumulation and clearance in patients with skin lesions by in vivo surface-detected fluorescence spectroscopy. Lasers Med Sci 1999, 14:112-122.
21. Riddle C.C., Terrell S.N., Menser M.B., Aires D.J., Schweiger E.S. A review of photodynamic therapy (PDT) for the treatment of acne vulgaris. J Drugs Dermatol 2009, 8(11):1010-1019.
22. Lesar A., Ferguson J., Moseley H. A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin. Photodermatol Photoimmunol Photomed 2009, 25(4):191-195.
23. van den Boogert J., van Staveren H.J., de Bruin R.W., Siersema P.D., van Hillegersberg R. Fractionated illumination for oesophageal ALA-PDT: effect on blood flow and PpIX formation. Lasers Med Sci 2001, 16(1):16-25.
24. Mosterd K., Thissen M.R., Nelemans P., et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 2008, 159(4):864-870.
25. Pogue B.W., Sheng C., Benevides J., et al. Protoporphyrin IX fluorescence photobleaching increases with the use of fractionated irradiation in the esophagus. J Biomed Opt 2008, 13(3):034009.
26. Puizina-Ivic N., Zorc H., Vanjaka-Rogosic L., Miric L., Persin A. Fractionated illumination improves the outcome in the treatment of precancerous lesions with photodynamic therapy. Coll Antropol 2008, 32(Suppl. 2):67-73.
27. De Vijlder H.C., Middelburg T., De Bruijn H.S., et al. Optimizing ALA-PDT in the management of non-melanoma skin cancer by fractionated illumination. G Ital Dermatol Venereol 2009, 144(4):433-439.
28. O'Connor A.E., Gallagher W.M., Byrne A.T. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 2009, 85(5):1053-1074.
29. Kennedy J.C., Pottier R.H., Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990, 6(1-2):143-148.
30. Juzenas P., Sorensen R., Iani V., Moan J. Clearance of protoporphyrin IX from mouse skin after topical application of 5-aminolevulinic acid and its methyl ester. Proc SPIE 1999, 3563:161-166.
31. Aalders M.C., van d V., Star W.M., Sterenborg H.J. A mathematical evaluation of dose-dependent PpIX fluorescence kinetics in vivo. Photochem Photobiol 2001, 74(2):311-317.
32. Star W.M., Aalders M.C., Sac A., Sterenborg H.J. Quantitative model calculation of the time-dependent protoporphyrin IX concentration in normal human epidermis after delivery of ALA by passive topical application or lontophoresis. Photochem Photobiol 2002, 75(4):424-432.
33. Vaidyanathan V.V., Rastegar S., Fossum T.W., et al. A study of aminolevulinic acid-induced protoporphyrin IX fluorescence kinetics in the canine oral cavity. Lasers Surg Med 2000, 26(4):405-414.
34. Schubert H.L., Raux E., Matthews M.A., et al. Structural diversity in metal ion chelation and the structure of uroporphyrinogen III synthase. Biochem Soc Trans 2002, 30(4):595-600.
35. Cornah J.E., Roper J.M., Pal S.D., Smith A.G. Measurement of ferrochelatase activity using a novel assay suggests that plastids are the major site of haem biosynthesis in both photosynthetic and non-photosynthetic cells of pea (Pisum sativum L.). Biochem J 2002, 362(Pt. 2):423-432.
36. Hart D., Piomelli S. Simultaneous quantitation of zinc protoporphyrin and free protoporphyrin in erythrocytes by acetone extraction. Clin Chem 1981, 27(2):220-222.
37. The European Agency for the Evaluation of Medicinal Products Iron dichloride and iron sulphate. EMEA/MRL 1998, 383:98.
38. Tapiero H., Gate L., Tew K.D. Iron: deficiencies and requirements. Biomed Pharmacother 2001, 55(6):324-332.
39. Labbe R.F., Vreman H.J., Stevenson D.K. Zinc protoporphyrin: a metabolite with a mission. Clin Chem 1999, 45(12):2060-2072.
40. Pinna K., Kelley D.S., Taylor P.C., King J.C. Immune functions are maintained in healthy men with low zinc intake. J Nutr 2002, 132(7):2033-2036.
41. Sturniolo G.C., Mestriner C., Irato P., Albergoni V., Longo G., D'Inca R. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients. Am J Gastroenterol 1999, 94(2):334-338.
42. Roth J.R., Lawrence J.G., Bobik T.A. Cobalamin (coenzyme B12): synthesis and biological significance. Annu Rev Microbiol 1996, 50:137-181.
43. Hercberg S., Rouaud C. Nutritional anaemia. Child Trop 1981, 133:1-36.
44. Bucher J.R., Hailey J.R., Roycroft J.R., et al. Inhalation toxicity and carcinogenicity studies of cobalt sulfate. Toxicol Sci 1999, 49(1):56-67.
45. Choudry K., Brooke R.C., Farrar W., Rhodes L.E. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 2003, 149(1):124-130.
46. Campbell S.M., Morton C.A., Alyahya R., Horton S., Pye A., Curnow A. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol 2008, 159(2):387-393.
47. Curnow A., Campbell S.M. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: further explanation of a dose-escalating pilot study conducted primarily to consider the safety of this pharmacological modification. Br J Dermatol 2010, 162(1):224-225.